付燕,纪世博,邢卉春

• 1:首都医科大学附属北京地坛医院肝病中心

摘要(Abstract)：

<正>腹水是肝硬化三大并发症(腹水、肝性脑病、消化道出血)中最常见的一种,也是最常见的导致患者入院的并发症。为了给内科医生提供成人肝硬化腹水的首选诊断、治疗和预防方法,2012年美国肝病研究学会(AASLD)对"成人肝硬化腹水处理指南"进行了更新[1](以下简称"新指南")。该指南对每项建议均提供了的推荐意见的类别(反映了利益与风险)和循证医学证据等级(评价其强度或可信度)(见表1、表2)[2]。用于指导有临床

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 付燕,纪世博,邢卉春

参考文献(References)：

• [1]Runyon.BA.Management of adult patients with ascites due tocirrhosis:update 2012.Hepatol.2013.www.aasld.org/practiceguidelines/Documents/Ascites Due To Cirrhosis ManagementUpdate 2012.pdf.
• [2]Shiffman RN,Shekelle P,Overhage J M,et al.Standardizedreporting of clinical practice guidelines:a proposal from theConference on Guideline Standardization[J].Ann.Intern.Med,2003,139(6):493-498.
• [3]Runyon BA,Montano AA,Akriviadis EA,et al.The serum-ascites albumin gradient is superior to the exudate-transudateconcept in the differential diagnosis of ascites[J].Ann InternMed,1992,117(3):215-220.
• [4]Sheer TA,Joo E,Runyon BA.Usefulness of serum pro-brain-type natriuretic peptide in distinguishing ascites due to cirrhosisfrom ascites due to heart failure[J].J Clin Gastroenterol,2010,44(1):e23-e26.
• [5]Cattau EL Jr,Benjamin SB,Knuff TE,et al.The accuracyof the physical exam in the diagnosis of suspected ascites[J].JAMA,1982,247(8):1164-1166.
• [6]Runyon BA.Ascites and spontaneous bacterial peritonitis.In:Feldman M,Friedman LS,Brandt LJ,eds.Sleisenger andFordtran’s Gastrointestinal and Liver Disease.9th ed[M].Philadelphia:Saunders Elsevier,2010:1517-1541.
• [7]Runyon BA.Paracentesis of ascitic fuid:a safe procedure[J].Arch Intern Med,1986,146(11):2259-2261.
• [8]Grabau CM,Crago SF,Hoff LK,et al.Performance standardsfor therapeutic abdominal paracentesis[J].Hepatology,2004,40(2):484-488.
• [9]Sakai H,Sheer TA,Mendler MH,et al.Choosing the locationfor non-image guided abdominal paracentesis[J].LiverInternational,2005,25(5):984-986.
• [10]Garg H,Sarin SK,Kumar M,et al.Tenofovir improves theoutcome in patients with spontaneous reactivation of hepatitisB presenting as acute-on-chronic liver failure[J].Hepatol,2011,53(3):774-780.
• [11]Addolorato G,Leggio L,Ferrulli A,et al.Effectiveness andsafety of baclofen for maintenance of alcohol abstinencei n a l c o h o l-d e p e n d e n t p a t i e n t s w i t h l i v e r c i r r h o s i s:randomized,double-blind controlled study[J].Lancet,2007,370(9603):1915-1922.
• [12]Wong F,Blei AT,Blendis LM,et al.A vasopressin receptorantagonist(VPA-985)improves serum sodium concentrationin patients with hyponatremia:a multicenter,randomized,placebo-controlled trial[J].Hepatol,2003,37(1):182-191.
• [13]Schrier RW,Gross P,Gheorghiade M,et al.Tolvaptan,a selective oral vasopressin V2-receptor antagonist,forhyponatremia[J].N Engl J Med,2006,355(20):2099-2112.
• [14]Wong F,Watson H,Gerbes A,et al.Satavaptan for themanagement of ascites in cirrhosis:efficacy and safety acrossthe spectrum of ascites severity[J].Gut,2012,61(1):108-116.
• [15]Spahr L,Villeneuve JP,Tran HK,et al.Furosemideinducednatriuresis as a test to identify cirrhotic patients with refractoryascites[J].Hepatol,2001,33(1):28-31.
• [16]Pockros PJ,Reynolds TB.Rapid diuresis in patients withascites from chronic liver disease:the importance of peripheraledema[J].Gastroenterology,1986,90(6):1827-1833.
• [17]Hernandez AF,Greiner MA,Fonarow GC,et al.Relationshipbetween early physician follow-up and 30-day redmissionamong Medicare beneficiaries hospitalized for heart failure[J].JAMA,2010,303(17):1716-1722.
• [18]Llach J,Ginès P,Arroyo V,et al.Prognostic value of arterialpressure,endogenous vasoactive systems,and renal function incirrhotic patients admitted to the hospital for the treatment ofascites[J].Gastroetnerology,1988,94(2):482-487.
• [19]Gines P,Angeli P,Lenz K,et al.EASL clinical practiceguideline on the management of ascites,spontaneous bacterialperitonitis,and hepatorenal syndrome[J].J Hepatol,2010,53(3):397-417.
• [20]Arroyo V,Gines P,Gerbes AL,et al.Definition and diagnosticcriteria of refractory ascites and hepatorenal syndrome incirrhosis[J].Hepatology,1996,23(1):164-176.
• [21]Singh V,Dhungana SP,Singh B,et al.Midodrine in patientswith cirrhosis and refractory ascites:a randomized pilotstudy[J].J Hepatol,2012,56(2):348-354.
• [22]Gines P,Uriz J,Calahorra B,et al.Transjugular intrahepaticportosystemic shunting versus paracentesis plus albumin forrefractory ascites in cirrhosis[J].Gastroenterology,2002,123(6):1839-1847.
• [23]Rabie R,Cazzaniga M,Salerno F,et al.The effect of cirrhoticcardiomyopathy on the post-TIPS outcome of patients treatedfor complications of portal hypertension[J].Hepatology,2006,44:444A.
• [24]Mendler MH,Agarwal A,Trimzi M,et al.A new highlysensitive point of care screen for spontaneous bacterialperitonitis using a leukocyte esterase method[J].J Hepatol,2010,53(3):477-483.
• [25]Runyon BA.Monomicrobial nonneutrocytic bacterascites:avariant of spontaneous bacterial peritonitis[J].Hepatology,1990,12(4 Pt 1):710-715.
• [26]Felisart J,Rimola A,Arroyo V,et al.Randomized comparativestudy of efficacy and nephrotoxicity of ampicillin plustobramycin versus cefotaxime in cirrhotics with severeinfections[J].Hepatology,1985,5:457-462.
• [27]Fernandez J,Acevedo J,Castro M,et al.Prevalence andrisk factors of infections by resistant bacteria in cirrhosis:aprospective study[J].Hepatology,2012,55(5):1551-1561.
• [28]Akriviadis EA,Runyon BA.The value of an algorithmin differentiating spontaneous from secondary bacterialperitonitis[J].Gastroenterology,1990,98(1):127-133.
• [29]Tito L,Rimola A,Gines P,et al.Recurrence of spontaneousbacteria peritonitis in cirrhosis:frequency and predictivefactors[J].Hepatology,1988,8(1):27-31.
• [30]Rongey C,Lim NH,Runyon BA.Cellulitis in patients withcirrhosis and edema:an under-recognized complicationc u r r e n t l y m o r e c o m m o n t h a t s p o n t a n e o u s b a c t e r i a lperitonitis[J].Open Gastro J,2008,2:24-27.
• [31]Fernández J,Ruiz del Arbol L,Gómez C,et al.Norfloxacinvs ceftriaxone in the prophylaxis of infections in patients withadvanced cirrhosis and hemorrhage[J].Gastroenterology,2006,131(4):1049-1056.
• [32]Terg R,Llano K,Cobas S,et al.Effect of oral ciprofloxacinon aerobic gram-negative fora of cirrhotic patients:results ofshort and long term administration with variable does[abstract][J].Hepatology,1996,24:455A.
• [33]Younossi ZM,McHutchison JG,Ganiats TG.An economicanalysis of norfloxacin prophylaxis against spontaneousbacterial peritonitis[J].J Hepatol,1997,27(2):295-298.
• [34]Rolando N,Gimson A,Philpott-Howard J,et al.Infectioussequelae after endoscopic sclerotherapy of oesophageal varices:role of antibiotic prophylaxis[J].J Hepatol,1993,18(3):290-294.
• [35]Salerno F,Gerbes A,Ginès P,et al.Diagnosis,prevention and.treatment of the hepatorenal syndrome in cirrhosis[J].Gut,2008,84(998):662-670.
• [36]Verna EC,Brown RS,Farraud E,et al.Urinary neutrophilgelatinase associated lipocalin predicts mortality and identifiesacute kidney injury in cirrhosis[J].Dig Dis Sci:2012,57(9):2362-2370.
• [37]Sort P,Navasa M,Arroyo V,et al.Effect of intravenousalbumin on renal impairment and mortality in patients withcirrhosis and spontaneous bacterial peritonitis[J].N Engl JMed,1999,341(6):403-409.
• [38]Tyagi P,Sharma P,Sharma BC,et al.Prevention of hepatorenalsyndrome in patients with cirrhosis and ascites:a pilotrandomized control trial between pentoxifylline and placebo[J].Eur J Gastro Hep,2011,23(3):210-217.
• [39]Orman ES,Lok ASF.Outcomes of patients with chest tubeinsertion for hepatic hydrothorax[J].Hepatol Int,2009,3(4):582-586.
• [40]Angeli P,Volpin R,Gerunda G,et al.Reversal of type Ihepatorenal syndrome with the administration of midodrine andoctreotide[J].Hepatology,1999,29(6):1690-1697.
• [41]Belghiti J,Durand F.Abdominal wall hernias in the setting ofcirrhosis[J].Sem Liv Dis,1997,17(3):219-226.
• [42]Trotter JF,Suhocki PV.Incarceration of umbilical herniafollowing transjugular intrahepatic portosystemic shunt fortreatment of ascites[J].Liv Transpl Surg,1999,5(3):209-210
• [43]Sarit C,Eliezer A,Mizrahi S.Minimally invasive repair ofrecurrent strangulated umbilical hernia in cirrhotic patient withrefractory ascites[J].Liv Transpl,2003,9(6):621-622.
• [44]Angermayr B,Cejna M,Koenig F,et al.Survival in patientsundergoing transjugular intrahepatic portosystemic shunt:ePTFE-covered stentgrafts versus bare stents[J].Hepatology,2003,38(4):1043-1050.